[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 519
Citations 0
Invited Commentary
July 9, 2020

Locally Advanced Rectal Cancer—Precision Therapy in a Time of Moving Targets and Competing Goals

Author Affiliations
  • 1Department of Surgery, University of Minnesota Medical School, Minneapolis
  • 2Department of Medicine, University of Minnesota Medical School, Minneapolis
  • 3Clinical Trials Office–Solid Tumor Unit, Masonic Cancer Center, University of Minnesota, Minneapolis
JAMA Oncol. Published online July 9, 2020. doi:10.1001/jamaoncol.2020.2208

In this issue of JAMA Oncology, Diefenhardt and colleagues1 report a post hoc analysis of the previously published German CAO/ARO/AIO-04 trial2 and found that the ability of patients with rectal cancer to complete planned neoadjuvant (but not adjuvant) therapy was associated with improved disease-free survival. The authors concluded “the findings emphasize the need for appropriate trial design with optimized nCRT [neoadjuvant chemoradiotherapy] dose and schedule and supportive strategies to facilitate good adherence and precision delivery, especially for intensified nCRT.”1 Few would dispute this broad point, but the greater challenge lies in aligning their recommendations with current paradigms of rectal cancer treatment, which have evolved dynamically since the CAO/ARO/AIO-04 study.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×